ADMP

Adamis Pharmaceuticals Corporation
0.1238
0.0007 (0.57%)
Company Name Stock Ticker Symbol Market Type
Adamis Pharmaceuticals Corporation ADMP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0007 0.57% 0.1238 19:58:27
Open Price Low Price High Price Close Price Prev Close
0.12 0.1188 0.135 0.12 0.1231
more quote information »

Recent News

Date Time Source Heading
3/30/202310:00IHNWFeaturedNextech3D.ai Enters Asian Market with Major 3D Modeling Deal to Revolutionize E-Commerce
3/17/202308:09EDGARAdditional Proxy Soliciting Materials (definitive) (defa14a)
3/17/202308:07EDGARCurrent Report Filing (8-k)
3/16/202316:24GLOBEAdamis Pharmaceuticals Reports Full Year 2022 Financial..
3/16/202315:59EDGARAnnual Report (10-k)
3/14/202317:26EDGARCurrent Report Filing (8-k)
3/14/202316:01GLOBEAdamis Pharmaceuticals Schedules Fourth Quarter and Full..
3/14/202308:30GLOBEAdamis Pharmaceuticals Announces $3.0 Million Registered..
2/27/202316:05GLOBEAdamis Pharmaceuticals and DMK Pharmaceuticals Announce..
2/23/202307:09EDGARCurrent Report Filing (8-k)
2/22/202316:01GLOBENasdaq Grants Adamis Pharmaceuticals’ Request for Extension..
11/14/202216:59EDGARQuarterly Report (10-q)
11/14/202216:48EDGARCurrent Report Filing (8-k)
11/14/202216:10GLOBEAdamis Pharmaceuticals Reports Third Quarter 2022 Financial..
11/07/202216:05GLOBEAdamis Pharmaceuticals Schedules Third Quarter 2022..
10/04/202206:16EDGARCurrent Report Filing (8-k)
10/04/202206:09EDGARCurrent Report Filing (8-k)
10/03/202216:30GLOBEAdamis Announces Review of Strategic Alternatives
9/23/202217:08EDGARCurrent Report Filing (8-k)
9/23/202217:06EDGARProspectus Filed Pursuant to Rule 424(b)(5) (424b5)
9/21/202207:30GLOBEAdamis Provides Update on the Phase 2/3 Trial of Tempol in..
9/20/202206:03EDGARNotice of Effectiveness (effect)
9/12/202216:05GLOBEAdamis Provides an Enrollment Update on the Phase 2/3 Study..
9/12/202206:05EDGARCurrent Report Filing (8-k)
9/09/202217:13EDGARSecurities Registration Statement (simplified Form) (s-3)
8/18/202215:09EDGARAdditional Proxy Soliciting Materials (definitive) (defa14a)
8/15/202206:36EDGARAdditional Proxy Soliciting Materials (definitive) (defa14a)
8/12/202217:00GLOBEAdamis Pharmaceuticals Announces Results of Annual Meeting..
8/10/202216:11EDGARCurrent Report Filing (8-k)
8/10/202216:05EDGARQuarterly Report (10-q)
8/10/202216:02GLOBEAdamis Pharmaceuticals Reports Second Quarter 2022 Financial..
8/08/202207:30GLOBEAdamis Pharmaceuticals Schedules Second Quarter 2022..
8/01/202209:38EDGARCurrent Report Filing (8-k)
7/31/202208:15TRMNDawson James Sticks to Its Hold Rating for Adamis Pharma..
7/29/202215:36EDGARAdditional Proxy Soliciting Materials (definitive) (defa14a)
7/29/202208:00GLOBELeading Independent Proxy Advisory Firm ISS Recommends..
7/29/202207:30GLOBEAdamis Pharmaceuticals Provides Update on Clinical Study..
7/21/202207:30GLOBEAdamis Pharmaceuticals Issues Letter to Stockholders
7/07/202216:38EDGARProxy Statement (definitive) (def 14a)
7/07/202216:26EDGARSmall Company Offering and Sale of Securities Without..
7/06/202206:05EDGARAdditional Proxy Soliciting Materials (definitive) (defa14a)
7/06/202206:05EDGARCurrent Report Filing (8-k)
6/17/202216:34EDGARProxy Statement - Notice of Shareholders Meeting..
6/17/202216:26EDGARCurrent Report Filing (8-k)
6/01/202208:00GLOBEAdamis Pharmaceuticals Provides Update on Clinical Study..
5/27/202216:14EDGARStatement of Changes in Beneficial Ownership (4)
5/26/202217:08EDGARCurrent Report Filing (8-k)
5/26/202216:43EDGARInitial Statement of Beneficial Ownership (3)
5/26/202216:31EDGARStatement of Changes in Beneficial Ownership (4)
5/26/202216:05GLOBEAdamis Appoints Vickie Reed to Board of Directors
5/19/202206:05EDGARCurrent Report Filing (8-k)